{"title":"Exploring synergistic therapy for metabolic dysfunction-associated steatotic liver disease.","authors":"Anas Zaher, Hassan Elsaygh","doi":"10.5114/pg.2025.151891","DOIUrl":null,"url":null,"abstract":"<p><p>The global epidemic of obesity has led to a surge in metabolic-associated steatotic liver disease (MASLD), which poses a significant global health burden. Current therapeutic strategies primarily focus on lifestyle modifications, weight loss interventions, and the use of pharmacological agents such as glucagon-like peptide-1 receptor agonists (GLP-1RAs). Recently, the FDA approved resmetirom, a selective thyroid hormone receptor-β agonist. Both GLP-1RAs and resmetirom have individually demonstrated promising results in managing MASLD and associated metabolic disorders. However, the potential synergistic effects of combining these agents remain unexplored. This paper discusses the rationale for exploring the combination therapy of resmetirom and GLP-1RAs for managing MASLD.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"20 2","pages":"115-120"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224265/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2025.151891","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The global epidemic of obesity has led to a surge in metabolic-associated steatotic liver disease (MASLD), which poses a significant global health burden. Current therapeutic strategies primarily focus on lifestyle modifications, weight loss interventions, and the use of pharmacological agents such as glucagon-like peptide-1 receptor agonists (GLP-1RAs). Recently, the FDA approved resmetirom, a selective thyroid hormone receptor-β agonist. Both GLP-1RAs and resmetirom have individually demonstrated promising results in managing MASLD and associated metabolic disorders. However, the potential synergistic effects of combining these agents remain unexplored. This paper discusses the rationale for exploring the combination therapy of resmetirom and GLP-1RAs for managing MASLD.
期刊介绍：
Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
